A Study of BBI608 Administrated With FOLFIRI + Bevacizumab in Adult Patients With Metastatic Colorectal Cancer
Status:
Completed
Trial end date:
2017-01-01
Target enrollment:
Participant gender:
Summary
This is an open-label, multicenter, phase 1 study of BBI608 in combination with FOLFIRI +
Bavacizumab. This study population is adult Japanese patients with metastatic colorectal
cancers in FOLFIRI + Bevacizumab combination therapy.